Head-To-Head Review: Harrow (NASDAQ:HROW) versus Vivani Medical (NASDAQ:VANI)

Vivani Medical (NASDAQ:VANI) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Profitability

This table compares Vivani Medical and Harrow’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Harrow	-5.57%	19.59%	2.26%

Risk & Volatility

Vivani Medical has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vivani Medical and Harrow”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61 million	($0.40)	-3.00
Harrow	$272.30 million	5.76	-$5.14 million	($0.41)	-102.61

Harrow has higher revenue and earnings than Vivani Medical. Harrow is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vivani Medical and Harrow, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1	1	2	0	2.25
Harrow	1	2	8	0	2.64

Vivani Medical currently has a consensus price target of $3.75, suggesting a potential upside of 212.50%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 65.03%. Given Vivani Medical’s higher possible upside, research analysts clearly believe Vivani Medical is more favorable than Harrow.

Summary

Harrow beats Vivani Medical on 7 of the 13 factors compared between the two stocks.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.